Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
The Foundation for Sarcoidosis Research Awards $300,000 to Support Early-Career Investigators Through the Sarcoidosis Research Fellowship Grant
July 24, 2024 13:16 ET
|
Foundation for Sarcoidosis Research
CHICAGO, July 24, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is pleased to announce that Dr. Greer Waldrop, University of California, San Francisco, and Dr. Miles...
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
July 24, 2024 10:00 ET
|
ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 24, 2024 08:05 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
July 22, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
July 18, 2024 10:20 ET
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
萬聯行在香港獲得Targretin®️(Bexarotene)用於皮膚T細胞淋巴瘤的上市批准
July 16, 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
万联行获得Targretin®(Bexarotene 贝沙罗汀)在香港用于皮肤T细胞淋巴瘤的市场批准
July 16, 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司(“Main Life”)今天宣布Targretin®(贝沙罗汀)胶囊在香港获得上市许可,用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 (Cutaneous T-cell...
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
July 16, 2024 02:54 ET
|
MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.